Surgical Science Sweden AB (publ) SUS
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait for the Q1 report; consider a small add (up to ~10%) only after confirmed stabilization in license revenue/margins.
Strong balance sheet, higher share of license revenue and confirmed margin improvement outweigh remaining uncertainty around 2026 revenue.
Sentiment has strengthened further after the strong report with focus on recovery and higher margins.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 20 Sep 2026 — The report shows higher license revenue and margin improvement after the Intuitive effect proved smaller than feared.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Surgical Science Sweden AB develops VR-based simulators and software for surgical training, including robotic surgery, endoscopy and ultrasound. It sells to both education customers (hospitals/universities) and industry customers via OEM/license agreements. 2026 carries elevated uncertainty after an Intuitive-related arrangement ended, expected to reduce license revenue.
Bull case
Higher share of license revenue lifts gross margin and shows the business model remains robust even during disruptions from individual customers.
Bear case
License revenue may still decline more than expected in the second half of 2026 if the Intuitive effect materializes fully.
Why this signal
Strong balance sheet, higher share of license revenue and confirmed margin improvement outweigh remaining uncertainty around 2026 revenue.
Recent news
Q2 report published 19 August showed revenue of SEK 254.5 M, adjusted EBIT margin of 15 % and net result of SEK 20.9 M. License revenue rose 44 % and the Intuitive impact was smaller than feared. The share rose approximately 24 % on the report day. Redeye awarded the company top scores in both valuation and momentum in September.